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The biologic underpinnings of posttraumatic stress disorder (PTSD)
have not been fully elucidated. Previous work suggests that alter-
ations in the immune system are characteristic of the disorder.
Identifying the biologic mechanisms by which such alterations occur
could provide fundamental insights into the etiology and treatment
of PTSD. Here we identify specific epigenetic profiles underlying
immune system changes associated with PTSD. Using blood samples
(n = 100) obtained fromanongoing, prospective epidemiologic study
in Detroit, theDetroit NeighborhoodHealth Study,we appliedmeth-
ylation microarrays to assay CpG sites from more than 14,000 genes
among 23 PTSD-affected and 77 PTSD-unaffected individuals. We
show that immune system functions are significantly overrepre-
sentedamongtheannotationsassociatedwithgenesuniquelyunme-
thylatedamongthosewithPTSD.Wefurtherdemonstrate thatgenes
whose methylation levels are significantly and negatively correlated
with traumatic burden show a similar strong signal of immune func-
tion among the PTSD affected. The observed epigenetic variability in
immune function by PTSD is corroborated using an independent bi-
ologic marker of immune response to infection, CMV—a typically la-
tent herpesviruswhoseactivitywas significantlyhigher amongthose
with PTSD. This report of peripheral epigenomic and CMV profiles
associatedwith mental illness suggests a biologic model of PTSD eti-
ology in which an externally experienced traumatic event induces
downstreamalterations in immune functionbyreducingmethylation
levels of immune-related genes.
epidemiology | methylation | cytomegalovirus | cumulative trauma |
psychiatry
Posttraumatic stress disorder (PTSD) is an atypical psycholog-ical and physiological response that can occur among persons
exposed to a potentially traumatic event (PTE) involving life
threat, serious injury, or death. To obtain a diagnosis of PTSD,
reactions to the traumatic stressor must include fear, helplessness,
or horror. Additionally, persons must experience symptoms from
three distinct yet cooccurring domains, including intrusive recol-
lections or reexperiencing of the PTE, accompanied by intense
psychological distress or physiologic reactivity; persistent avoid-
ance of feeling, thoughts, or activities that are associated with the
trauma, which may involve amnesia or numbness to external
stimuli; and increased arousal that may involve insomnia, hyper-
vigilance, or an exaggerated startle response. These cooccurring
symptoms must be present for a minimum of 1 month, and, to
warrant a PTSD diagnosis, must be severe enough to impair an
individual’s social, occupational, or interpersonal functioning (1).
Exposure to traumatic stress is a prerequisite for a PTSD di-
agnosis and distinguishes it fromother psychopathologies. Indeed,
PTSD has been described as a specific phenotype that develops as
a result of a failure to contain the normal stress response (2),
resulting in dysregulation of the hypothalamic–pituitary–adrenal
(HPA) axis, one of the body’s major stress response systems that
interacts reciprocally with the immune system to maintain ho-
meostasis (3). PTSD-affected and -unaffected individuals have
been shown to have distinct expression patterns in genes involved
in immune activation (4, 5) and in genes that encode neural and
endocrine proteins (4, 6).
Recent work suggests that epigenetic DNAmethylation changes
may accompany lifetime experiences and alter gene expression
profiles (7). This work has particular promise for the study of PTSD
given the direct link between an experience (i.e., a PTE) and
a physiologic manifestation of illness. However, to the best of our
knowledge, there have been no studies to date that have docu-
mented differences in epigenetic methylation patterns among per-
sons with vs. without PTSD, althoughmurine (8, 9) and human (10)
studies of genes involved in the HPA axis suggest that epigenetic
signatures relevant to thedisordermaywell exist. Inparticular, given
the body of work suggesting an association between PTSD and
alterations in the immune system (3), it is plausible that PTSDmay
be associated with epigenetic changes in immune system–related
gene clusters. If this were the case it would provide clues to a po-
tential mechanism through which an externally experienced trau-
matic event changes geneexpression, thus altering immune function
and resulting in other possible physiologic alterations.
Here we report results from a large-scale investigation of epige-
netic methylation and immune function profiles among PTSD-
affected and -unaffected individuals, drawing on samples obtained
from theDetroitNeighborhoodHealth Study (DNHS). TheDNHS
is an ongoing, longitudinal epidemiologic study investigating cor-
relates of PTSD and other mental disorders in the city of Detroit
(additional information on the study is available in SI Appendix). In
wave 1 of this study, prevalences of major depressive disorder
(MDD) and generalized anxiety disorder (GAD) were in line with
national levels (SI Appendix); however, lifetime and 12-month
prevalences of PTSDweremore than twice that previously reported
in other epidemiologic studies (14.4% and 10.0% vs. 6.8% and
3.5%, respectively) (11) (SI Appendix). This finding may be due in
part to an increased exposure to assaultive violence, which has been
associated with a higher conditional risk of PTSD compared with
other traumatic event types (12): exposure to assaultive violence in
the DNHS survey sample was 50.8%, a level that far exceeds that
reported for suburban communities surrounding the city of Detroit
(13) but is consistent with levels reported for other major US urban
areas (12).Thesefindings suggest that PTEexposure canvaryacross
disparate social environments (12), with resulting negative psycho-
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logical and physiologic consequences. The relatively high burden of
PTSD-related psychopathology in theDNHS study population thus
offers a uniqueopportunity to assess theepigenetic correlatesof this
disorder, which may, in the longer term, assist efforts to identify
effective interventions.
Results
WeusedDNAderived fromwholeblood from100 individuals, 23 of
whommet the criteria for lifetimePTSD,whoparticipated inwave 1
of the DNHS. Using the humanmethylation27 (HM27) DNA
Analysis BeadChip by Illumina, we assessed methylation profiles at
more than 27,000 CpG sites covering more than 14,000 genes (ad-
ditional details regarding experimental protocol and PTSD de-
termination are available in SI Appendix). PTSD-affected and
-unaffected individuals did not differ significantly with respect to
age, sex, race, or peripheral blood mononuclear cell count (Table
S1), and all 100 individuals had been exposed to at least one PTE.
We focused our initial efforts on identifying genes that were
uniquely methylated or unmethylated among PTSD-affected vs.
-unaffected individuals. DNA methylation beta values are continu-
ous variables between 0 (completely unmethylated) and 1 (com-
pletely methylated). In this analysis, we classified probes with beta
values <0.2 as unmethylated, and probes with a value of >0.8 as
methylated. Although there is currently no consensus regarding how
best to model methylation data (14), these values are conservative
compared with other cutoffs that have previously been used to de-
terminemethylated and unmethylated sites on theHM27 BeadChip
(15) and compared with the analogous percentage of methylation
reference values often adopted in the cancer literature to represent
unmethylated and methylated genes, respectively (e.g., ref. 16). We
averaged the methylation levels for each gene in each of the two
groups and then determined the number of shared and uniquely
methylated/unmethylated genes in each comparison (Fig. 1). The
number of uniquely unmethylated genes did not differ significantly
between PTSD-affected and -unaffected individuals (χ2 = 0.49, 1 df,
P= 0.485); however, there was a significant difference between the
two groups with respect to the number of uniquely methylated genes
(χ2 = 46.10, 1 df, P < 0.0001). Gene expression analysis of the genes
commonly methylated and unmethylated in both groups suggests
that, in general, a methylated state corresponds to lower gene ex-
pression levels and, conversely, anunmethylated state corresponds to
higher gene expression levels (Fig. S1). Pyrosequencing and targeted
DNA sequencing of select loci (n = 5) confirmed the direction of
initial methylation results from the HM27 BeadChip and the exis-
tence of invariant sequence at the probe target regions (SIAppendix).
To gain insight into the biologic significance of these uniquely
methylated and unmethylated genes, we undertook functional an-
notation clustering (FAC)analyses. Table1presents the results from
the top three FACs determined from uniquely methylated and
unmethylated genes in eachof the twogroups (the full set of results is
available inTable S2, Table S3, Table S4, andTable S5). Fig. 2A and
B illustrate two sample FACs, and the genes they contain, de-
termined from the PTSD-affected group. Clusters were identified by
selecting theoverrepresented annotation that conveyed the broadest
biologicmeaningwithin eachFAC.Consistentwithpreviousfindings
from gene expression (4, 5) and psychoeneuroimmunologic studies
(3), each of the top three FACs determined from uniquely unme-
thylated genes among PTSD-affected individuals shows a strong
signature of immune system involvement. This signature includes
genes fromthe innate immune system(e.g.,TLR1andTLR3), aswell
as from genes that regulate innate and adaptive immune system
processes (e.g., IL8, LTA, and KLRG-1). In contrast, pathways and
processes relevant to organismal development in general—and
neurogenesis in particular—figure prominently among the genes
uniquely unmethylated in the PTSD-unaffected group (e.g.,CNTN2
andTUBB2B; Fig. S2). Notably, similar clusters were obtained using
an alternative approach based on genes differentially methylated
between the two groups at P < 0.01, with annotations in the top five
FACs that include signal, cell proliferation, developmental process,
neurologic system process, and inflammatory response (complete
results of all FAC analyses are available in Table S2, Table S3, Table
S4, Table S5, Table S6, Table S7, Table S8, Table S9, and Table S10
and inFig. S2,Fig. S3,Fig. S4,Fig. S5,Fig.S6,Fig. S7,Fig. S8,Fig. S9,
Fig. S10, Fig. S11, Fig. S12, Fig. S13, Fig. S14, Fig. S15, Fig. S16, Fig.
S17, Fig. S18, Fig. S19, Fig. S20, Fig. S21, Fig. S22, and Fig. S23).
PTSD often cooccurs with other mental illnesses, in particular
depression and other anxiety disorders (17). To investigate the effect
that comorbiditymay have on our results, we assessedwhether genes
were significantly differentially methylated among those affected
only by PTSD (n= 8), those affected by PTSD and one or more of
MDDandGAD(n=15), and those unaffected by anyof these three
psychopathologies (n = 53). ANOVA tests confirmed that there
were significant differences in methylation levels across the three
groups in 345 genes (P < 0.01); however, only three genes showed
methylation levels that were significantly different at this alpha level
between those affected only by PTSD and those affected by PTSD
and another disorder (Tukey honestly significant difference), sug-
gesting that comorbidity did not unduly influence our results.
PTSD is diagnosed in reference to a specific traumatic event
rather than multiple potential traumas (1). Epidemiologic studies,
however, have demonstrated that, among the PTE exposed, a ma-
jority of individuals have been exposed to more than one traumatic
event (12, 13) and that multiple such exposures can correlate with
symptom severity (18). To investigate whether cumulative trauma is
associated with distinctive methylation profiles among PTSD-
affected vs. -unaffected individuals, we assessed the correlation
between number of PTEs and methylation levels for each CpG site
represented on the HM27 microarray. Compared with PTSD-
unaffected individuals, PTSD-affected individuals showednearly six
times as many genes (176 vs. 30) with significant (P< 0.01) negative
correlations to number of PTEs experienced and nearly seven times
as many genes (170 vs. 25) with significant positive correlations to
number of PTEs experienced (range of Spearman correlation
coefficients, ρ:−0.698 to−0.526and0.527 to0.736among thePTSD
affected; and−0.460 to−0.295 and 0.292 to 0.389 among the PTSD
unaffected, respectively). Results from FAC analyses conducted
on these four gene sets are presented in Table 2. Here again we see
a distinct signature of immune-relatedmethylation profiles among
the PTSD-affected group only. More specifically, we see methyl-
ation profiles that are suggestive of immune activation among
persons withmore PTE exposure in the genes that are significantly
negatively correlated with increasing number of PTEs—a pattern
reflective of that observed for the uniquely unmethylated genes in
this same group (Table 1).
To corroborate these immune-related findings with an in-
dependent, physiologic marker of immune function, we assessed
antibody levels to CMV. CMV is a persistent herpesvirus highly
Unmethylated Genes Methylated Genes
detceffA-DSTPdetceffA-DSTP detceffanU-DSTPdetceffanU-DSTP
180 9987 167 195 1504 82
Fig. 1. Number of methylated and umethylated genes according to PTSD
status. Red indicates the genes uniquely methylated or unmethylated in the
PTSD-affected group, blue indicates the genes uniquely methylated or
unmethylated in the PTSD-unaffected group, and green indicates the genes
commonly methylated or unmethylated in both groups. Methylated genes
were defined as those genes with average β values of >0.8, and unmethy-
lated genes were defined as those genes with average β values of <0.2.










































prevalent in most human populations (19). CMV infection drives
many of the alterations associated with an aging immune system
(20), and its value as a sentinel biomarker indicative of a compro-
mised immune system is increasingly being recognized (21). If
PTSD, as hypothesized here, is the physiologic manifestation of
a traumatic insult that results in epigenetic changes and subsequent
gene expression patterns that alter immune function, it would be
plausible to expect alterations in immune response to CMV among
persons affected vs. unaffected by PTSD. In the present study, the
titersofCMV-specificantibody, as reflected inopticaldensity ratios,
were significantly different betweenPTSD-affected and -unaffected
individuals (mean ratios 3.37 and 2.32, respectively, Welch’s t sta-
tistic = 2.48, 37 df, P = 0.016; Fig. 3). These results suggest that
PTSD is associated with compromised immune reactivity to CMV.
Discussion
Drawing on a unique, ongoing epidemiologic study, we have
documented a distinct signature reflecting immune activation
among PTSD-affected individuals, using both epigenetic markers
and a marker indicative of a compromised immune system—the
antibody response to CMV. Although preliminary, the findings
here are consistent with a model whereby exposure to a PTE
induces changes in methylation profiles among some persons and
that these changes result in changes in gene expression associ-
ated with altered immune function, demonstrated here through
differences in immune response to CMV.
Epigenomic Phenotype of PTSD-Affected vs. -Unaffected Individuals.
Among the many analyses performed in this work, the immune-
related functions identified in the PTSD-affected group were con-
sistently identified only among gene sets with relatively lower levels
of methylation (Tables 1 and 2). Demethylation has previously been
shown to correlate with increased expression in several immune
system–related genes (reviewed in ref. 22), including some identified
here [e.g., IL8 (23)]. In contrast, methylation profiles among the
PTSD-unaffected are distinguished by neurogenesis-related func-
tional annotations. Neural progenitor cells have previously been
identified in the adult human hippocampus (24); however, stress can
inhibit cell proliferation and neurogenesis in this brain region
(reviewed in ref. 25), and recent work suggests that adult neuro-
genesis may be regulated by components of the immune system
(reviewed in ref. 26). Thus, immune dysfunction among persons with
PTSDmay be influenced by epigenetic profiles that are suggestive of
immune activation or enhancement and also by an absence of epi-
genetic profiles that would be consistent with the development of
normal neural-immune interactions (27).
Among the genes uniquely methylated in the PTSD-affected
group, it is striking that the second most enriched cluster—sensory
perception of sound—directly reflects one of the three major
symptom clusters that define the disorder (Fig. 3B). Genes in this
FAC thatmay be particularly salient to this symptomdomain include
otospiralin (OTOS),which showsdecreasedexpression inguineapigs
after acoustic stress (28) and otoferlin (OTOF), mutations in which
have been linked to nonsyndromic hearing loss in humans (29). Ex-
aggerated acoustic startle responses, oftenmeasuredvia heart rate or
skin conductance after exposure to a sudden, loud tone, have been
well documentedamong thePTSDaffected (30)andare indicativeof
a hyperarousal state that characterizes this symptom domain. No-
tably, prospective studies have demonstrated that an elevated startle
response is a consequenceofhavingPTSD,because the responsewas
notpresent immediately afterexposure to traumabutdevelopedwith
time among trauma survivors who developed the disorder (30, 31).
Although more recent work suggests that such reactions may be
influenced by a preexisting hypersensitivity to contextual threat (32),
these findings are generally consistent with our hypothesis that PTE
exposure may induce epigenetic changes that produce physiologic
alterations among PTSD-affected individuals.
Assessment of Comorbidity. Our finding that methylation levels did
notdiffer significantly between individuals affectedbyPTSDalonevs.
Table 1. Functional annotation cluster analyses of uniquely methylated and unmethylated genes
Uniquely unmethylated Uniquely methylated
Group Cluster No. of genes Enrichment score Cluster No. of genes Enrichment score
PTSD affected Inflammatory response 26 2.38 Signal 55 2.16
Immune response 38 1.5 Sensory perception of sound 15 1.07
Innate immune response 11 1.48 Response to xenobiotic stimulus 5 1.02
PTSD unaffected Developmental process 50 2.67 Signal 32 1.77
Generation of neurons 37 2.2 Lipase activity 6 1.22
Intracellular organelle 102 1.97 Calcium ion binding 10 1.17
All genes are identified in terms of DAVID IDs; genes can appear in more than one cluster.
Table 2. Functional annotation cluster analyses of genes significantly correlated with number of PTEs
Group Correlation Cluster No. of genes Enrichment score
PTSD affected Negative Immune response 38 2.14
Defense response 56 2.11
Nucleotide receptor activity 11 1.82
Positive I-κB kinase/NF-κB cascade 10 1.38
Cell proliferation 13 1.34
Positive regulation of signal transduction 21 1.31
PTSD unaffected Negative Transporter activity 9 1.13
Membrane 17 1.05
Transmembrane transporter activity 10 0.99
Positive Calcium binding 6 1
Secreted 5 0.49
Nonmembrane bound organelle 11 0.44
P < 0.01; all genes are reported in terms of DAVID IDs; genes can appear in more than one cluster.



















those affected by PTSD and other mood–anxiety disorders lends bi-
ologic support to previous epidemiologic findings. Population-based
studies have shown that after traumatic event exposure, although
there is a higher prevalence of other psychopathologies, PTSD is the
sentinel diagnosis, andother diagnoses seldomappearwithout PTSD
(33). In biologic terms, that so few genes show significantly different
methylation levels in post hoc comparisons between individuals af-
fected by PTSD alone vs. PTSD and other comorbid disorders sug-
gests that the hypothesized underlying biologic cascade leading to
PTSD (i.e., PTE exposure→epigenetic changes→gene expression
changes→PTSD) operates among all persons with the disorder, re-
gardless of whether they have other axis I psychological disorders.
Future work should verify these results in other, independent cohorts
using additional measures of comorbidity.
Maintenance of DNA Methylation and Imprinted Genes. DNA
methylation patterns are maintained and created by DNA methyl-
transferases, a family of enzymes that, in mammals, catalyze the
transferof amethyl group to cytosine residuespredominantly, butnot
exclusively (34), at CpG dinucleotide sites (35). This enzymatic ma-
chinery both sets up methylation patterns early in development and
maintains them through subsequent somatic cell division during an
individual’s lifetime. In this context, it is noteworthy that a gene
encoding one of these enzymes (DNMT3B) is both uniquely unme-
thylated and shows significantly less methylation (P < 0.017) in the
PTSD-affected group; and that another, closely related gene
(DNMT3L) is significantly more methylated (P = 0.037) among
individuals with vs. without PTSD. Although the bulk of these genes’
activity is typically thought to occur early in development (36), recent
work has suggested that their enzymatic productsmay also play a role
in DNA methylation maintenance during somatic cell division (35).
This suggests that the underlying machinery responsible for creating
and maintaining methylation patterns may function differently
among those with vs. without PTSD, producing downstream pheno-
typeswithbothpathophysiologicandpsychopathologicaldimensions.
Similarly, imprinted genes—genes silenced through epigenetic
mechanisms early in development in a parent-of-origin fashion—
often function as disease susceptibility genes through deletion and/or
inactivation of loci that normally follow a monoallelic expression
pattern. Perhaps not surprisingly, a handful of genes known to be
involved in well-known diseases of imprinting, specifically Praeder-
Willi syndrome (PWS) and Angelmann syndrome (AS), appear on
theuniquelymethylatedandunmethylatedgene lists; of interest here,
however, is theway inwhich themethylation pattern seems to “track”
both the PTSDphenotype and the phenotype associatedwith each of
these disorders. Two genes,NDN andMAGEL2, localize to the PWS
deletion region and are normally expressed from the paternal allele
(37, 38). NDN appears on the uniquely unmethylated gene list for
those without PTSD, suggesting the likelihood of proper expression;
MAGEL2, on the other hand, appears on the uniquely methylated
gene list for those with PTSD, suggesting reduced expression in
a manner akin to what occurs in PWS. ATP10A, a gene that maps to
thegenomic regionmost commonlydeleted inASand that is typically
expressed from thematernal allele (39), also appears on the uniquely
methylated PTSD list, suggesting again reduced expression in
a manner concurrent with AS. These examples suggest that methyl-
Fig. 2. Sample FAC heat maps in the PTSD-affected group. Shown are the genes and associated annotations for FAC cluster 3 (A) and 2 (B) determined from


















Fig. 3. Optical density ratios of CMV antibody levels among PTSD-affected
and -unaffected individuals. Levels were significantly higher in the PTSD-
affected group (Welch’s t statistic = 2.48, 37 df, P = 0.016).










































ation profiles of imprinted genesmay contribute to PTSD-associated
phenotypes, in a manner that remains to be more fully elucidated.
Study Limitations. Our study includes a number of limitations that
may limit the generalizability of its results. The cross-sectional
analyses reported here leave us unable to infer at present whether
the observed distinctive methylation profiles and CMV antibody
levels are a consequence of PTSDorwhether they are indicative of
biologic vulnerabilities that existed among the PTSD affected
before the onset of their disorder. In addition, given the limited
number of PTSD-affected individuals included in this study, we
were unable to address in this work whether distinct methylation
profiles may exist within the PTSD-affected group that could re-
flect distinct subtypes and/or phenotypic heterogeneity within this
clinical syndrome, as has previously been suggested (2, 40). Finally,
our epigenetic data were collected fromDNA derived from whole
blood, which includes a heterogeneous mixture of cell types; as
such, we were unable to assess blood cell–specific differences in
methylation status, which would have to be accounted for when
replicating the present findings in other, longitudinal cohorts.
Concluding Remarks. PTSD is an uncommon response to stress.
Although nearly 90% of individuals are exposed to a traumatic
event during their lifetime (13), only a minority go on to develop
the disorder. Nevertheless, this illness is one of the more common
and disabling psychopathologies in the United States: with a life-
time prevalence of 6.8% and a 12-month prevalence of 3.5% (11),
impairment of proper role functioning due to PTSD is significantly
worse than in a number of commonly occurring chronic medical
disorders (41). In this study, we found that Detroit residents show
lifetime and 12-month PTSD prevalences more than twice these
national averages, suggesting that such PTSD-associated impair-
ment may be borne disproportionately among individuals residing
in urban social environments. Identification of the biologic
underpinnings of PTSD will be crucial for facilitating the de-
velopment of appropriate psychological and/or pharmacologic
interventions, particularly in the wake of an increasing number of
military veterans returning home after recent wars worldwide.
Materials and Methods
Participants. Our analysis made use of a subset of participants from the DNHS
(for more details regarding the DNHS, readers are referred to SI Appendix).
The sample for this study consisted of 100 DNHS participants. Forty weremale
and 60 female; 14% were white, 79% African American, and 7% other race;
14% had less than a high school education, whereas 86%were at least a high
school graduate; and the average agewas 45.8 years (Table S1). TheDNHSwas
approved by the institutional review board at the University of Michigan.
Assessment of PTSD. Individual assessment of PTSD symptomswere conducted
using the PTSD checklist (PCL-C) (42), a 17-item self-report measure of Di-
agnostic and Statistical Manual of Mental Disorders (DSM-IV) symptoms (13,
43), and additional questions about duration, timing, and impairment or
disability due to the symptoms.
Participants were initially asked to identify PTEs that they experienced in
the past from a list of 19 events. PTSD symptoms were then assessed by
referencing two traumatic events that the respondentmay have experienced:
one that the participant regarded as the worst and one randomly selected
event from the remaining PTEs a respondent may have experienced.
Respondents were considered affected by lifetime PTSD if all six DSM-IV
criteria weremet in reference to either theworst or the randomevent. All 100
individuals included in this study were exposed to at least one PTE; among
these, 23 were PTSD affected and 77 were unaffected. Additional psycho-
pathologies were assessed as described in SI Appendix.
Microarray Analyses. Bisulfite conversion of whole blood–derived DNA samples
was performed using the EZ-96 DNA methylation kit from Zymo Research. One
microgramofeachsample(includingcontrols)wassubjectedtobisulfiteconversion
according to the manufacturer’s recommended protocol. Experimental controls
included replicates for two samples to assess variation throughout the experi-
mentalprocess (i.e., frominitialbisulfiteconversionthroughmicroarrayanalysis),as
well as one sample of completely unmethylated and completely methylated hu-
man DNA, commercially available through Zymo Research, in each of the two 96-
well plates used in the bisulfite conversion step. All control replicates were placed
on separate microarray chips, and the remaining samples were assigned to micro-
array chips at random, without regard to PTSD status. Bisulfite-converted DNA
samples were subjected to methylation profiling via the HM27 DNA Analysis
BeadChip by Illumina according to the manufacturer’s recommended protocol.
Using this platform, methylation levels were determined for 27,578 CpG dinu-
cleotides spanning 14,495 genes in eachof the 100 test samples. The resultingdata
were background normalized and exported for additional analysis using the R
package v2.9.0 (44) and SAS software v9.2 (45). Correlation coefficients of the two
replicated samples were 0.81 and 0.89, respectively. Average beta values for the
methylated controls was 0.93 and the correlation 0.96. Average beta values and
correlation of unmethylated controls were 0.17 and 0.98, respectively.
Initial analyses focused on identifying genes corresponding to probes (CpG
sites) that were uniquely methylated or unmethylated among PTSD-affected
vs. -unaffected individuals.Wecalculatedtheaveragebetavaluesof thesamples in
the twogroups (PTSDaffectedandunaffected) andclassifiedprobeswithaverage
beta values<0.2 as unmethylated and probes with an average beta value of>0.8
as methylated. Each probe was identified to be uniquely methylated or uniquely
unmethylated if itwasmethylated—orunmethylated—in justonegroup.Because
it was possible that a gene may be associated with more than one probe on the
HM27 BeadChip, we created two subsets of data consisting only of (i) methylated
probes in either the PTSD-affected or -unaffected group, and (ii) unmethylated
probes ineither thePTSD-affectedor -unaffectedgroup.Then, foreach subset,we
removed duplicate records based on the gene symbol and methylation status in
each of the two groups. In this way, genes with two or more probes that showed
similar results (bothprobesuniquelymethylated in thePTSD-affectedgroup)were
not counted twice. Conversely, geneswith two ormore probes showing different
results (e.g.. one probe is uniquely methylated in the PTSD-affected group,
whereas the other probe is uniquely methylated in the PTSD-unaffected group)
were counted twice (ormore); each result is thus accounted for. Theproportionof
uniquely methylated and unmethylated genes among PTSD-affected vs. -un-
affected individuals was compared using McNemar’s χ2 test.
DifferentialmethylationanalysisbetweenthePTSD-affectedand-unaffected
groups was conducted for each probe using the Wilcoxon test. We identified
a probe to be significantly differentiallymethylated if P< 0.01. This analysiswas
extended to assess differential methylation among participants with no psy-
chopathology, those who were PTSD affected only, and those who were PTSD
affectedandaffectedbyoneormoreofMDDandGAD; for this analysis,ANOVA
was initially performed followed by the Tukey honestly significant difference
test, a post hoc pairwise comparison test.
To assess the correlation between the number of PTEs experienced and
methylation levels of each probe among PTSD-affected vs.-unaffected indi-
viduals,we stratifiedby PTSD status and analyzed the correlationbetween the
number of lifetime PTEs and methylation levels of each probe, separately for
each group (PTSD affected and PTSD unaffected). Spearman’s rho was calcu-
lated for each probe, and results were accepted as significant if P < 0.01.
HM27probesanalyzedasdescribedabovewereassignedtogenesonthebasis
of annotation files available from Illumina on May 20, 2009. Genes identified
through the above analyses were assessed for functional significance using the
Database for Annotation, Visualization and Integrated Discovery (DAVID) (46,
47). Results were obtained with the FAC tool, with options set to their default
values, using annotations available in DAVID as of June–August 2009.
Experimental Procedures: CMV Analyses. CMV IgG antibody levels were tested
using a standard commercial ELISA kit for detecting type-specific IgG anti-
body in serum (Inverness Medical Innovations; 425200CE). Serum samples
were eluted in buffer before being pipetted in duplicate into antigen-coated
microtiter wells. Through a series of incubation and wash steps, the CMV
antibodies of the sample were anchored to the microtiter plate and linked to
a secondary reactive antibody. Absorbance was quantified by a microplate
reader set at 450 nm. Concentrations were calculated by optical density
(positive ≥1.10, equivocal 0.91–1.09, negative ≤0.9). Antibody levels are
expressed in terms of mean optical density ratio. The Inverness Medical
Innovations kit exhibits high specificity of 93.9% and a sensitivity of 96.4%
when compared with other CMV IgG ELISA procedures. A t test was con-
ducted to compare CMV optical density (OD) ratios between the two groups.
Gene Expression Analysis. Publicly accessible data on gene expression were
obtained from the National Center for Biotechnology Information Gene
Expression Omnibus (GEO) database. Whole blood–derived gene expression
levels from 40 samples were obtained for analysis from the following
datasets: GDS2952, GDS2519 (48), GDS1331 (49), and GDS596 (50). All sam-
ples were derived from healthy control individuals in these datasets. Com-
monly methylated and unmethylated probes were obtained from our data



















as presented in green in Fig. 1. RefSeqs of the GEO data were obtained from
Affymetrix NetAffx Analysis Center batch query as of July 27, 2009 and then
matched with the RefSeqs (accession) in the Illumina data for additional
analysis. Raw gene expression values of commonly methylated and unme-
thylated probes were log base 2 transformed and normalized by median
centering. The values were then averaged for each probe, and a t test was
performed to compare the mean expression levels between the two groups.
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